Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial-Reference-Cited by-同舟云学术

Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial

Published:2023-07-15 Issue:1 Volume:164 Page:141-146
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Mallick Supriya,Gupta Subhash,Amariyil Adila,Kunhiparambath Haresh,Laviraj M. A.,Sharma Seema,Sagiraju Hari Krishna Raju,Julka Pramod Kumar,Sharma Dayanand,Rath Goura Kishor

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Neurology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11060-023-04391-7.pdf

Reference29 articles.

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

2. Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926

3. Roa W, Brasher PMA, Bauman G, Anthes M, Bruera E, Chan A et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol Off J Am Soc Clin Oncol 22(9):1583–1588

4. Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D et al (2015) International atomic energy agency randomized phase III Study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol Off J Am Soc Clin Oncol 10(35):4145–4150

5. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates for newly diagnosed and recurrent glioblastoma: a review of recent clinical trials;Current Opinion in Neurology;2024-09-13

2. PROTON THERAPY FOR ADULT-TYPE DIFFUSE GLIOMA: A SYSTEMATIC REVIEW;Critical Reviews in Oncology/Hematology;2024-09

3. Simultaneous boost radiotherapy versus conventional dose radiotherapy for patients with newly diagnosed glioblastoma: a multi-institutional analysis;Scientific Reports;2024-04-23

4. Glioblastoma: quality of life as a key element in evaluation of radiation treatment effectiveness;Український радіологічний та онкологічний журнал;2024-03-22

5. Treatment Outcomes after Dose-Escalated Moderately Hypofractionated Radiotherapy for Frail Patients with High-Grade Glioma;Cancers;2023-12-21